Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQADXL)

• Drug Name: 3,7-Bis(2-hydroxyethyl)icaritin Drug Info
• Synonyms: 3,7-Bis(2-hydroxyethyl)icaritin; UNII-5U58D99D1L; CHEMBL498486; 5U58D99D1L; SCHEMBL18533069; BDBM50272529; 3,7-Bis(2-hydroxyethoxy)-5-hydroxy-4'-methoxy-8-(3-methyl-2-butenyl)flavone; 1067198-74-6; 4H-1-Benzopyran-4-one, 5-hydroxy-3,7-bis(2-hydroxyethoxy)-2-(4-methoxyphenyl)-8-(3-methyl-2-buten-1-yl)-

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 25058047
  CAS Number: CAS 1067198-74-6
  TTD Drug ID: DMQADXL

Molecule-Related Drug Atlas

Drug(s) Targeting Phosphodiesterase 5A (PDE5A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tadalafil	DMJZHT1	Benign prostatic hyperplasia	GA90	Approved	[3]
Udenafil	DM1IQRP	Erectile dysfunction	HA01.1	Approved	[4]
Vardenafil	DMTBGW8	Cystic fibrosis	CA25	Approved	[5]
Dipyridamole	DMXY30O	Atrial fibrillation	BC81.3	Approved	[6]
Papaverine	DMCA9QP	Brain ischaemia	8B1Z	Approved	[7]
Avanafil	DM75CXN	Erectile dysfunction	HA01.1	Approved	[8]
Rhucin	DM3ADGP	Erectile dysfunction	HA01.1	Approved	[9]
ICARIIN	DMOJQGT	N. A.	N. A.	Phase 3	[1]
EXISULIND	DMBY56U	Colorectal cancer	2B91.Z	Phase 3	[10]
PF-489791	DM3C8GQ	Chronic obstructive pulmonary disease	CA22	Phase 2	[11]

Drug(s) Affected By cGMP-specific 3',5'-cyclic phosphodiesterase (PDE5A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Rhucin	DM3ADGP	Erectile dysfunction	HA01.1	Approved	[12]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[13]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[14]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[15]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[16]
Tadalafil	DMJZHT1	Benign prostatic hyperplasia	GA90	Approved	[17]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[18]
Vardenafil	DMTBGW8	Cystic fibrosis	CA25	Approved	[17]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[19]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[20]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Phosphodiesterase 5A (PDE5A)	TTJ0IQB	PDE5A_HUMAN	Inhibitor	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
cGMP-specific 3',5'-cyclic phosphodiesterase (PDE5A)	OTT8Q1AP	PDE5A_HUMAN	Gene/Protein Processing	[2]

References

• [1] Potent inhibition of human phosphodiesterase-5 by icariin derivatives. J Nat Prod. 2008 Sep;71(9):1513-7.
• [2] Potent inhibition of human phosphodiesterase-5 by icariin derivatives. J Nat Prod. 2008 Sep;71(9):1513-7.
• [3] Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. Rheumatology (Oxford). 2009 Jun;48 Suppl 3:iii25-31.
• [4] Increased expression of the nitric oxide synthase gene and protein in corpus cavernosum by repeated dosing of udenafil in a rat model of chemical d... Asian J Androl. 2009 Jul;11(4):435-42.
• [5] The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol. 2002 Dec 4;40(11):2006-12.
• [6] Anti-platelet therapy: phosphodiesterase inhibitors.Br J Clin Pharmacol.2011 Oct;72(4):634-46.
• [7] Effects of icariin on cGMP-specific PDE5 and cAMP-specific PDE4 activities. Asian J Androl. 2003 Mar;5(1):15-8.
• [8] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [9] cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium. J Pharmacol Exp Ther. 2009 Sep;330(3):884-91.
• [10] Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res. 2000 Jul 1;60(13):3338-42.
• [11] Highlights of the society for medicinesresearch symposium held december 10th 2009 at the national heart and lung institute, London, UK. Drugs of the Future 2010, 35(4): 349-358.
• [12] Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology. 1999 Jul;91(1):307-10. doi: 10.1097/00000542-199907000-00041.
• [13] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [14] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [15] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [16] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [17] Pharmacotherapy of erectile dysfunction: focus on cardiovascular safety. Expert Opin Drug Saf. 2005 May;4(3):531-40. doi: 10.1517/14740338.4.3.531.
• [18] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [19] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [20] Comparative effects of raloxifene, tamoxifen and estradiol on human osteoblasts in vitro: estrogen receptor dependent or independent pathways of raloxifene. J Steroid Biochem Mol Biol. 2009 Feb;113(3-5):281-9.